Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NG-350A Monotherapy and with Checkpoint Inhibitor in Advanced Epithelial Tumors
NCT03852511Phase 1Completed
- Sponsor
- Akamis Bio
- Start
- Feb 2019
- Primary completion
- Feb 2022
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of NG-350A in Epithelial tumor (2 arms), sponsored by Akamis Bio. Primary endpoint: Incidence of adverse events, serious adverse events, and DLTs. Started Feb 2019; status: completed.
02
Drugs
NG-350A
03
Conditions
Epithelial tumor
Beyond the preview
Go deeper on NCT03852511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852511.